Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23149258 | 0.87 | IDO1 (0.43) | IDO1PLAUENPP2ALDH1A1HTT | |
| SCHEMBL791863 | 0.83 | IDO1 (0.58) | IDO1ACLYALDH1A1TACR1MAPT | |
| SCHEMBL16397054 | 0.82 | PLAU (0.36) | IDO1PLAUENPP2ALDH1A1HTT | |
| SCHEMBL19794310 | 0.80 | ENPP2 (0.36) | ENPP2ALDH1A1 | |
| SCHEMBL16410320 | 0.79 | IDO1 (0.36) | IDO1PLAU | |
| SCHEMBL13262677 | 0.75 | IDO1 (0.45) | IDO1ACLYTACR1 | |
| SCHEMBL3624689 | 0.75 | PRKCE (0.37) | IDO1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL14861048 | 0.73 | IDO1 (0.48) | IDO1ACLYALDH1A1TACR1MAPT | |
| SCHEMBL22519892 | 0.73 | IDO1 (0.48) | IDO1PLAUALDH1A1TACR1HTT | |
| SCHEMBL16954773 | 0.73 | IDO1 (0.43) | IDO1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | IDO1 917/4885PLAU 4171/4885ACLY 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.